The first time ketamine wandered into my psychiatric life, it didn’t knock. It didn’t send a calendar invite.
It just showed up like that cousin who used to be “a little wild,” disappeared for years, and returns at Thanksgiving
wearing a suit and handing out résumés.

In the early 2000s, ketamine’s reputation lived mostly in operating rooms and cautionary tales. In medicine, it was
a reliable anesthetic. In pop culture, it was shorthand for “don’t do that at a music festival.” In psychiatry, it was
the kind of name you heard in a hallway conversation and filed away under interesting but probably not my problem.

Then depressionespecially the stubborn, treatment-resistant kindkept being my problem. Not the “rough week, take a walk”
kind, but the “nothing touches this” kind. Patients who had done the therapy homework, tried multiple medications, slept
like garbage, woke up exhausted, and still looked at life like it was a room with all the exits bricked up.

Over the next two decades, ketamine moved from “intriguing research oddity” to “rapid-acting option we can’t ignore.”
It also dragged along some big questions about ethics, safety, access, hype, and how not to turn medical hope into a
checkout-cart subscription. This is my 20-year journey with ketamine: what surprised me, what sobered me, and what I wish
everyonepatients, families, clinicians, and the occasional overconfident internet influencerunderstood.

How Ketamine Entered the Conversation: When “Weeks” Was Too Slow

Psychiatry has long had a timing problem. Traditional antidepressants can be lifesaving, but for many people they take
weeks to workif they work. When someone is sinking fast, “come back in a month” can feel like telling a drowning person,
“Good news, swimming lessons start next season.”

Around the mid-2000s, the early clinical buzz got louder: low-dose ketamine could reduce depressive symptoms rapidly in
some patients, sometimes within hours. The idea sounded almost rude. We weren’t used to anything in depression care being
fastexcept, unfortunately, the parts we most feared.

My first reaction wasn’t “miracle.” It was “Waitketamine? That ketamine?” Medicine trains you to be both curious
and suspicious, like a raccoon with a stethoscope. I wanted to know: What’s the evidence? Who benefits? How long does it last?
What’s the costbiological, psychological, social?

Why a Psychiatrist Would Even Consider an Anesthetic

Because depression doesn’t politely stay inside diagnostic boundaries. Treatment-resistant depression often overlaps with anxiety,
trauma histories, chronic pain, insomnia, and the kind of exhaustion that makes even “small steps” feel like carrying groceries up Everest.
If a medication could offer rapid relief, it could create breathing roomenough space for therapy, lifestyle changes, and social support
to actually stick.

But rapid relief also invites rapid overconfidence. And overconfidence in psychiatry is how you end up with a waiting room full of people
who were promised a “reset button” and are now furious that the human brain doesn’t come with customer support.

The Science (Without the Yawn): Glutamate, Plasticity, and a Brain That Can Rebuild

For years, the public narrative about antidepressants centered on serotoninlike serotonin was a single magical knob you turn to “happy.”
Real brains are messier. Ketamine pushed the field to take glutamate seriously, the brain’s major excitatory neurotransmitter, and to think
in terms of circuits and connectivity.

Ketamine is known for blocking NMDA receptors, one of the main receptor types involved in glutamate signaling. But the antidepressant story
seems to be less “block one thing and feel great” and more “nudge the system, trigger a cascade, and temporarily open a window where the brain
can rewire.” Researchers have linked ketamine’s effects to synaptic plasticityessentially the brain’s ability to strengthen or form new
connections between neurons.

The “Critical Window” Idea

I started describing ketamine to trainees as “opening a window” rather than “installing a new personality.” Some patients reported that the
world looked the same, but felt more negotiable. The despair wasn’t gone, but it loosened its grip enough for the patient to do something
differentmake a call, take a shower, show up to therapy, or simply feel less trapped.

That framing matters. If ketamine increases plasticity, then what happens during that windowsupport, sleep, psychotherapy, routines, relationships
becomes even more important. Medication may open the door; it doesn’t redecorate the entire house.

From Research Curiosity to Real Patients: My First Ketamine Cases

The first patients I considered for ketamine weren’t casual “try anything” situations. They were the people who had been through multiple
evidence-based treatments, often including several medication trials and structured therapy. The decision wasn’t driven by novelty; it was driven
by necessity.

The early practical lessons were humbling:

• Screening is not optional. Not everyone is a good candidate, especially if there are uncontrolled medical issues or certain psychiatric risks.
• Set expectations like a professional pessimist. “Rapid” doesn’t mean “permanent,” and “better” doesn’t mean “cured.”
• Support systems matter. Ketamine works best when the rest of the care plan is strong, not when it’s being used as a substitute for everything else.

What a Typical Session Looked Like (And Why It’s Not a Spa Day)

In a medically supervised setting, ketamine treatment typically involves monitoringvital signs, symptom check-ins, and a plan for what to do if
someone gets too dissociated, anxious, nauseated, or hypertensive. Patients may feel detached, as if they’re observing themselves from a slight distance.
Some describe dreamlike perceptions. Others feel emotionally neutral, like their brain briefly took a quiet vacation.

There’s a myth that “if it’s psychedelic, it must be profound.” Sometimes it is. Sometimes it’s just weird. I’ve had patients report transcendent
experiences and patients report, with genuine disappointment, “Doc, I mostly thought about nachos.”

The Boom Years: Clinics, Cash, and the Problem of “Too Easy to Sell”

As ketamine gained visibility, clinics multiplied. Some were thoughtful, medically rigorous, and integrated with psychotherapy and follow-up care.
Others treated ketamine like a commodity: pay, spray/infuse, and please leave a five-star review.

When something offers rapid relief, the market moves faster than the evidence. That’s not a moral failing; it’s a predictable human phenomenon.
People suffering want help now. Clinicians want better tools. Investors want a growth curve. And social media wants a before-and-after montage.

My Ethical Checklist (A.K.A. “How to Not Become a Ketamine Influencer”)

• Medical oversight and monitoring: sedation, dissociation, and blood pressure effects are real considerations.
• Clear diagnosis and treatment plan: ketamine is an option within a broader strategy, not a standalone identity.
• Risk assessment: substance use history, psychosis risk, and medical conditions must be considered carefully.
• Follow-up: if a clinic can’t tell you what happens after the session, that’s not a planit’s a transaction.

The deeper issue is that ketamine can “work” fast enough to tempt us into skipping the slow work: therapy, habit change, relationship repair,
and addressing the life conditions that feed depression. But depression is rarely just chemistry. It’s chemistry in a context.

Esketamine (SPRAVATO) Changes the Landscape: Standardization Meets Reality

When intranasal esketamine (commonly known by the brand name SPRAVATO) arrived, the field took a collective exhale. Here was a ketamine-derived option
with FDA approval for specific depressive conditions, a structured safety program, and a clearer framework for how it should be administered.

The most important shift wasn’t just pharmacologyit was guardrails. Esketamine’s rollout emphasized monitored administration in certified
settings, observation after dosing, and a consistent protocol. For clinicians like me, it helped pull the conversation away from the Wild West and back
toward standard medical practice.

Why the Rules Matter

Ketamine and esketamine can cause sedation and dissociation. They can also affect blood pressure and carry risk of misuse. That’s why supervised dosing
isn’t bureaucratic theater; it’s safety. Anyone promising that ketamine is a “simple take-home mood vitamin” is either misinformed, overselling, or auditioning
for a regulatory warning letter.

At the same time, standardization doesn’t solve everything. Access remains uneven. Insurance coverage varies. And there’s still the human reality that no one
wants to schedule their mental health around a clinic chair twice a week like it’s spin classexcept spin class at least plays upbeat music.

Ketamine-Assisted Psychotherapy: When Relief Becomes Opportunity

One of the most meaningful developments over the years has been pairing ketamine treatment with psychotherapy. Not as a trendy add-on, but as a practical
response to what ketamine seems to do: create a period where mood improves and cognition becomes more flexible.

In that window, therapy can be more effective. Patients may be better able to challenge rigid, depressive thinking. They can practice new skills without
their brain immediately swatting them down. They may feel motivated enough to show up consistentlyan underrated miracle in depression care.

What “Integration” Looks Like in Real Life

Integration doesn’t require mystical incense or a therapist who calls themselves a “neuro-shaman.” It requires practical structure:

• Preparation: Clarify goals and coping strategies before treatment.
• Support during the window: Therapy sessions timed to capitalize on improved mood and plasticity.
• Skill-building: CBT techniques, behavioral activation, sleep routines, and stress regulation.
• Meaning-making: Turning relief into change, not just relief into relief.

The best outcomes I’ve seen weren’t from ketamine alone. They were from ketamine plus a well-built care plan, plus a patient who felt safe enough to try again.

Safety, Side Effects, and the “Please Don’t DIY Your Brain” Talk

Let’s be blunt: ketamine is not a casual supplement. It’s a powerful medication with real physiological and psychological effects. In medical settings,
those effects are managed. In unsupervised settings, those effects can become dangerousespecially with inconsistent dosing, variable formulations, or lack of monitoring.

Over the years, I’ve seen the same safety themes repeat:

Short-Term Effects to Plan For

• Dissociation: feeling detached from body or surroundings, typically time-limited but sometimes distressing.
• Sedation: impairment that requires observation and safe transportation afterward.
• Blood pressure changes: especially important for patients with cardiovascular risk.
• Nausea or dizziness: manageable, but not rare.

Longer-Term Concerns (Especially With Frequent Use)

• Misuse and dependence risk: ketamine is a controlled substance for a reason.
• Cognitive effects: frequent high-dose use is associated with cognitive concerns in non-medical contexts.
• Urinary symptoms: chronic heavy use has been linked to bladder problems; medical protocols aim to minimize risk.

The hardest part isn’t listing side effectsit’s communicating them without scaring people away from a treatment that might help. I tell patients:
“We can be hopeful and careful at the same time. That’s literally the job.”

What Ketamine Canand Can’tDo: The Difference Between Relief and Recovery

Ketamine can reduce depressive symptoms rapidly for some people. That matters. When you’ve watched patients crawl through years of failed treatments,
any real relief feels like someone opened a window in a locked room.

But ketamine isn’t a personality transplant. It doesn’t erase trauma. It doesn’t automatically fix relationships. It doesn’t pay your rent, solve discrimination,
or make grief stop grieving. And the effects may fade without a maintenance strategy.

I’ve learned to celebrate the “small” victories ketamine can enable:

• Getting out of bed without a negotiation that lasts until noon.
• Having enough energy to start therapy and actually participate.
• Feeling a reduction in suicidal thinking that creates safety and options.
• Reconnecting with routines that support long-term stability.

These outcomes are not flashy, but they are life-changing. Recovery is often built from boring bricks.

My 20-Year Takeaways: Hope, Humility, and a Little Bit of Humor

After two decades, I’m neither a ketamine evangelist nor a ketamine cynic. I’m something less dramatic: a clinician who has seen ketamine help,
has seen it disappoint, and has learned that the loudest story is rarely the most accurate one.

Three Things I Tell Almost Everyone

1. Choose a serious setting. Treatment should include medical screening, monitoring, and follow-up. If it feels like a checkout line, reconsider.
2. Use the window. If ketamine helps, invest in therapy, sleep, structure, and social support while your brain is more flexible.
3. Keep expectations realistic. “Rapid” is not the same as “forever,” and “better” is not the same as “done.”

And yes, I also tell them: “If someone on the internet claims ketamine ‘cures depression in one session,’ they are either selling something or auditioning for a sequel.”

Conclusion: Ketamine as a Tool, Not a Religion

Ketamine’s emergence in psychiatry has been one of the most significant shifts I’ve witnessed in my career. It challenged old assumptions about how quickly
depression can improve and pushed the field toward new biological targets and new clinical models. It also forced us to confront the risks of hype, the need for
safety standards, and the uncomfortable truth that access to novel treatments often reflects privilege more than need.

In the best cases, ketamine doesn’t “save” a person on its own. It gives them a foothold. And with that foothold, they can climbslowly, steadilytoward
a life that feels livable again.

If you’re considering ketamine therapy or esketamine nasal spray, treat it like the serious medical intervention it is: talk with a qualified clinician,
ask hard questions, and build a plan that includes more than the medication itself.

Bonus: 500 More Words From the Ketamine Trenches

If you’ve read this far, you deserve an extra storynot a miracle story, but the kind that actually happens in clinics when the lights are fluorescent and the
paperwork is aggressively unromantic.

Years ago, I worked with a patient I’ll call “D.” (Details changed, identity protected, dignity preservedmy favorite trio.) D. had the classic treatment-resistant
pattern: multiple medication trials, earnest therapy attempts, and the kind of fatigue that made every suggestion sound like an insult. When we discussed ketamine,
D. said, “So… I’ll trip and then I’m happy?” This is an excellent question, because it reveals how the public understands mental health: as a dramatic plot twist.

We talked instead about probability. About the goal being relief, not fireworks. About monitoring. About planning for the hours after treatment, when the mind might
feel quieter but the world is still the world. D. agreed, mostly because we framed it as a test of whether the brain could still respond to anything at all. That
question“Is my brain still reachable?”is often the hidden heartbreak of depression.

The first session didn’t produce angels singing. It produced something much less cinematic: D. slept better that night. The next morning, D. texted (through the
appropriate clinical channels, because I’m not trying to become a cautionary tale): “I don’t feel good. But I feel… not doomed.” That phrase stuck with me.
Not doomed. Psychiatry rarely gets “cured.” It gets “not doomed,” and then it gets to work.

Another patient, “M.,” had a different experience. M. felt relief after treatment but also felt unnerved by the dissociation. “I didn’t like not being in charge of
my mind,” M. said. We adjusted the plan, focused on grounding strategies, and spent time normalizing the experience: dissociation can be a side effect, not a
spiritual message. M. eventually did wellnot because ketamine was perfect, but because the plan flexed around the patient instead of forcing the patient to flex
around the plan.

Then there are the practical moments no glossy brochure mentions: the blood pressure cuff that feels like it’s squeezing secrets out of your arm, the patient who
insists on bringing a lucky hoodie (approved), the playlist debates (“No, we are not doing breakup ballads”), and the post-treatment snack discussions that are
strangely vital. One of my guiding principles is: if a person has been battling depression for years, let them have the apple juice.

The biggest lesson from these years is that ketamine is not a single eventit’s a chapter in a longer story. When it works, it can make the next chapter possible:
therapy becomes more doable, routines feel less impossible, hope stops feeling like a scam. When it doesn’t work, it still teaches us something: we need other tools,
other targets, other approaches. Either way, ketamine has forced psychiatry to become more creative, more urgent, andwhen we’re at our bestmore compassionate.